Orphagen Pharmaceuticals

Company Information
Address 11558 SORRENTO VALLEY RD STE 4
SAN DIEGO, CA, 92121-1312

http://www.orphagen.com

Information

DUNS: 103462128

# of Employees: 6


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. HLS-Small Molecule Discovery at Novel Target for Fetal Hemoglobin Induction

    Amount: $325,051.00

    DESCRIPTION provided by applicant Inherited beta globinopathies including sickle cell disease SCD and thalassemia HLS are chronic blood disorders resulting from defects in hemoglobin ...

    SBIRPhase I2015Department of Health and Human Services
  2. Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy

    Amount: $224,954.00

    DESCRIPTION provided by applicant The immune system is activated by expression of novel antigens on the surface of cancer cells leading to the elimination of tumor cells by a process referred to a ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  3. Small Molecule Target for Inhibition of Cortisol in Cushing's Syndrome

    Amount: $223,229.00

    ? DESCRIPTION (provided by applicant): Endogenous Cushing's syndrome is a classic dysfunction of the endocrine system caused by prolonged exposure to inappropriately high levels of cortisol. ...

    SBIRPhase I2014Department of Health and Human Services
  4. Selectin targeted ultrasound contrast agents for detection of acute coronary synd

    Amount: $446,635.00

    DESCRIPTION (provided by applicant): Retinitis pigmentosa (RP), a hereditary disease of the retina affecting 100,000 Americans, is the major cause of blindness in adults aged 25-60. There is no approv ...

    SBIRPhase I2013Department of Health and Human Services
  5. Neural Stem Cell-Selective Drug Target for Small Molecule Therapy of Brain Tumors

    Amount: $250,507.00

    DESCRIPTION (provided by applicant) Median survival from time of diagnosis of glioblastoma multiforme (GBM) or stage IV glioma, the most malignant form of brain cancer, is about one year, despite the ...

    SBIRPhase I2012Department of Health and Human Services
  6. A Novel Target for the Treatment of Endometriosis

    Amount: $220,839.00

    DESCRIPTION (provided by applicant): Endometriosis is a major cause of severe pelvic pain, pain during menstruation, dyspareunia and infertility in women of child-bearing age with an estimated 22 bil ...

    SBIRPhase I2011Department of Health and Human Services
  7. Inhibitor of Adrenal Steroid Synthesis for Cancer Treatment

    Amount: $520,358.00

    DESCRIPTION (provided by applicant): Orphagen has identified antagonists to an orphan receptor that regulates the major biosynthetic steps of steroid hormone synthesis in the adrenal cortex and gona ...

    SBIRPhase I2010Department of Health and Human Services
  8. Novel CNS Target for Sleep-Wake and Psychiatric Disorders

    Amount: $961,179.00

    DESCRIPTION (provided by applicant): Circadian regulation of behavioral, metabolic, and endocrine function is a fundamental homeostatic process. Disruption of the circadian clock has been linked to sl ...

    SBIRPhase II2009Department of Health and Human Services
  9. Small Molecule Inhibitors of Effector Th-17 Cells in Inflammatory Bowel Disease

    Amount: $266,559.00

    DESCRIPTION (provided by applicant): Inflammatory bowel disease (IBD), including Crohn's Disease and ulcerative colitis (UC), is a lifelong T cell- mediated inflammatory condition of the small intesti ...

    SBIRPhase I2008Department of Health and Human Services
  10. Feasibility Study of Novel Drug Target for Multiple Sclerosis

    Amount: $303,596.00

    DESCRIPTION (provided by applicant): A novel class of T helper cell, distinct from TH1 and TH2 cells, has been implicated in the development of murine experimentally-acquired encephalomyelitis (EAE), ...

    SBIRPhase I2007Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government